300702 天宇股份
已收盘 12-10 15:00:00
资讯
新帖
简况
天宇股份（300702）股东林洁质押190万股，占总股本0.55%
证券之星 · 11-21
天宇股份（300702）股东林洁质押190万股，占总股本0.55%
天宇股份（300702）披露修订公司章程及部分管理制度议案获股东大会通过，11月18日股价上涨0.15%
证券之星 · 11-18
天宇股份（300702）披露修订公司章程及部分管理制度议案获股东大会通过，11月18日股价上涨0.15%
11月14日天宇股份涨5.11%，信澳医药健康混合A基金重仓该股
证券之星 · 11-14
11月14日天宇股份涨5.11%，信澳医药健康混合A基金重仓该股
【机构调研记录】明亚基金调研天宇股份
证券之星 · 10-31
【机构调研记录】明亚基金调研天宇股份
天宇股份(300702)9月30日股东户数1.52万户，较上期减少8.06%
证券之星 · 10-30
天宇股份(300702)9月30日股东户数1.52万户，较上期减少8.06%
图解天宇股份三季报：第三季度单季净利润同比增长123.90%
证券之星 · 10-30
图解天宇股份三季报：第三季度单季净利润同比增长123.90%
天宇股份（300702）股东林洁质押760万股，占总股本2.18%
证券之星 · 10-27
天宇股份（300702）股东林洁质押760万股，占总股本2.18%
10月15日天宇股份发布公告，股东减持344.49万股
证券之星 · 10-15
10月15日天宇股份发布公告，股东减持344.49万股
天宇股份（300702）披露部分募集资金投资项目延期公告，9月29日股价下跌0.7%
证券之星 · 09-29
天宇股份（300702）披露部分募集资金投资项目延期公告，9月29日股价下跌0.7%
9月24日天宇股份现1笔折价21.44%的大宗交易 合计成交4846.07万元
证券之星 · 09-24
9月24日天宇股份现1笔折价21.44%的大宗交易 合计成交4846.07万元
天宇股份（300702）股东屠勇军质押1000万股，占总股本2.87%
证券之星 · 09-15
天宇股份（300702）股东屠勇军质押1000万股，占总股本2.87%
天宇股份(300702.SZ)：坎地沙坦酯片完成药品注册
智通财经 · 09-04
天宇股份(300702.SZ)：坎地沙坦酯片完成药品注册
9月1日天宇股份涨6.08%，兴业医疗保健混合A基金重仓该股
证券之星 · 09-01
9月1日天宇股份涨6.08%，兴业医疗保健混合A基金重仓该股
天宇股份最新公告：子公司制剂产品首次获得美国FDA批准文号
证券之星 · 08-29
天宇股份最新公告：子公司制剂产品首次获得美国FDA批准文号
【机构调研记录】凯石基金调研天宇股份
证券之星 · 08-26
【机构调研记录】凯石基金调研天宇股份
天宇股份股价微跌0.11% 机构调研透露上半年营收增长23.87%
金融界 · 08-26
天宇股份股价微跌0.11% 机构调研透露上半年营收增长23.87%
天宇股份（300702）2025年中报简析：营收净利润同比双双增长，应收账款上升
证券之星 · 08-24
天宇股份（300702）2025年中报简析：营收净利润同比双双增长，应收账款上升
天宇股份(300702.SZ)发布上半年业绩，归母净利润1.5亿元，增长180.96%
智通财经 · 08-22
天宇股份(300702.SZ)发布上半年业绩，归母净利润1.5亿元，增长180.96%
天宇股份最新公告：公司原料药获得CEP证书
证券之星 · 08-12
天宇股份最新公告：公司原料药获得CEP证书
8月11日天宇股份涨14.50%，兴业医疗保健混合A基金重仓该股
证券之星 · 08-11
8月11日天宇股份涨14.50%，兴业医疗保健混合A基金重仓该股
暂无数据
公司概况
公司名称：
浙江天宇药业股份有限公司
所属行业：
医药制造业
上市日期：
2017-09-19
主营业务：
浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是降血压类原料药及中间体、降血糖类原料药及中间体、抗凝血类原料药及中间体、制剂类、抗哮喘类原料药及中间体、降血脂类原料药及中间体。
发行价格：
22.41
{"stockData":{"symbol":"300702","market":"SZ","secType":"STK","nameCN":"天宇股份","latestPrice":24.56,"timestamp":1765350231000,"preClose":24.44,"halted":0,"volume":1598598,"delay":0,"changeRate":0.0049,"floatShares":211000000,"shares":348000000,"eps":0.5511,"marketStatus":"已收盘","change":0.12,"latestTime":"12-10 15:00:00","open":24.42,"high":24.71,"low":24.27,"amount":39159600,"amplitude":0.018,"askPrice":24.58,"askSize":14,"bidPrice":24.56,"bidSize":8,"shortable":0,"etf":0,"ttmEps":0.5511,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1765416600000},"marketStatusCode":5,"adr":0,"adjPreClose":24.44,"symbolType":"stock","openAndCloseTimeList":[[1765330200000,1765337400000],[1765342800000,1765350000000]],"highLimit":26.88,"lowLimit":22,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":347977159,"isCdr":false,"pbRate":2.29,"roa":"--","peRate":44.565415,"roe":"6.12%","epsLYR":0.16,"committee":0.68915,"marketValue":8546000000,"turnoverRate":0.0076,"status":0,"floatMarketCap":5186000000},"requestUrl":"/m/hq/s/300702/tweets","defaultTab":"tweets","newsList":[{"id":"2585141541","title":"天宇股份（300702）股东林洁质押190万股，占总股本0.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2585141541","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585141541?lang=zh_cn&edition=full","pubTime":"2025-11-21 18:35","pubTimestamp":1763721312,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份11月21日公开信息显示，股东林洁向招商证券股份有限公司合计质押190.0万股，占总股本0.55%。质押详情见下表：截止本公告日，股东林洁已累计质押股份2000.0万股，占其持股总数的16.39%，股东屠勇军已累计质押股份1530.0万股，占其持股总数的26.79%。天宇股份主营业务：化学原料药及中间体的研发、注册、生产和销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112100029688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2584955550","title":"天宇股份（300702）披露修订公司章程及部分管理制度议案获股东大会通过，11月18日股价上涨0.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584955550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584955550?lang=zh_cn&edition=full","pubTime":"2025-11-18 22:25","pubTimestamp":1763475922,"startTime":"0","endTime":"0","summary":"近日，浙江天宇药业股份有限公司召开2025年第三次临时股东大会，审议通过了《关于修订〈公司章程〉的议案》及《关于修订及制定公司部分管理制度的议案》。公告显示，上述议案采用现场与网络投票相结合的方式进行表决，《关于修订〈公司章程〉的议案》及部分子议案作为特别决议事项，已获出席会议股东所持有效表决权股份总数的2/3以上通过，会议表决结果合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111800039955.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2583575142","title":"11月14日天宇股份涨5.11%，信澳医药健康混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2583575142","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583575142?lang=zh_cn&edition=full","pubTime":"2025-11-14 16:37","pubTimestamp":1763109448,"startTime":"0","endTime":"0","summary":"证券之星消息，11月14日天宇股份涨5.11%，收盘报27.37元，换手率3.85%，成交量8.14万手，成交额2.21亿元。重仓天宇股份的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家；过去90天内机构目标均价为38.08。根据2025基金Q3季报公募基金重仓股数据，重仓该股的公募基金共3家，其中持有数量最多的公募基金为信达澳亚基金的信澳医药健康混合A。该公募基金现任基金经理为李点典。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111400025882.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2579107727","title":"【机构调研记录】明亚基金调研天宇股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2579107727","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579107727?lang=zh_cn&edition=full","pubTime":"2025-10-31 08:07","pubTimestamp":1761869231,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及10月30日披露的机构调研信息，明亚基金近期对1家上市公司进行了调研，相关名单如下：1）天宇股份 调研纪要：2025年制剂收入2.9亿元，展望2026年将迈入关键收获期，多个产品进入放量阶段，集采、零售及线上渠道协同发展。明亚基金成立于2019年，截至目前，资产管理规模2.71亿元，排名197/211；资产管理规模2.71亿元，排名170/211；管理公募基金数8只，排名157/211；旗下公募基金经理2人，排名177/211。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100011820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2579478113","title":"天宇股份(300702)9月30日股东户数1.52万户，较上期减少8.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579478113","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579478113?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:47","pubTimestamp":1761817625,"startTime":"0","endTime":"0","summary":"证券之星消息，近日天宇股份披露，截至2025年9月30日公司股东户数为1.52万户，较6月30日减少1335.0户，减幅为8.06%。在化学制药行业个股中，天宇股份股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.43万户。从股价来看，2025年6月30日至2025年9月30日，天宇股份区间涨幅为10.92%，在此期间股东户数减少1335.0户，减幅为8.06%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000034434.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2579180698","title":"图解天宇股份三季报：第三季度单季净利润同比增长123.90%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579180698","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579180698?lang=zh_cn&edition=full","pubTime":"2025-10-30 03:24","pubTimestamp":1761765850,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份2025年三季报显示，前三季度公司主营收入22.87亿元，同比上升18.36%；归母净利润2.21亿元，同比上升159.57%；扣非净利润2.1亿元，同比上升130.13%；其中2025年第三季度，公司单季度主营收入7.2亿元，同比上升7.91%；单季度归母净利润7142.11万元，同比上升123.9%；单季度扣非净利润6881.97万元，同比上升141.18%；负债率43.32%，投资收益-18.24万元，财务费用2428.62万元，毛利率39.14%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000003271.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702"],"gpt_icon":0},{"id":"2578501648","title":"天宇股份（300702）股东林洁质押760万股，占总股本2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2578501648","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2578501648?lang=zh_cn&edition=full","pubTime":"2025-10-27 19:19","pubTimestamp":1761563957,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份10月27日公开信息显示，股东林洁向招商证券股份有限公司合计质押760.0万股，占总股本2.18%。质押详情见下表：截止本公告日，股东林洁已累计质押股份2173.6万股，占其持股总数的17.81%，股东屠勇军已累计质押股份1530.0万股，占其持股总数的26.79%。天宇股份主营业务：化学原料药及中间体的研发、注册、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025102700029980.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2575068781","title":"10月15日天宇股份发布公告，股东减持344.49万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2575068781","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2575068781?lang=zh_cn&edition=full","pubTime":"2025-10-15 20:01","pubTimestamp":1760529684,"startTime":"0","endTime":"0","summary":"证券之星消息，10月15日天宇股份发布公告《天宇股份:关于控股股东、实际控制人之一致行动人减持股份触及1%整数倍暨减持计划实施完成的公告》，其股东屠善增于2025年10月10日至2025年10月15日间合计减持344.49万股，占公司目前总股本的0.9901%，变动期间该股股价下跌4.44%，截止10月15日收盘报24.54元。股东增减持详情见下表：根据天宇股份2025年中报公布的十大股东详情如下：以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025101500034679.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2571433749","title":"天宇股份（300702）披露部分募集资金投资项目延期公告，9月29日股价下跌0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2571433749","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2571433749?lang=zh_cn&edition=full","pubTime":"2025-09-29 22:43","pubTimestamp":1759156994,"startTime":"0","endTime":"0","summary":"截至2025年9月29日收盘，天宇股份报收于25.51元，较前一交易日下跌0.7%，最新总市值为88.77亿元。该股当日开盘25.67元，最高25.78元，最低25.06元，成交额达5349.4万元，换手率为1.0%。公司近日发布公告称，浙江天宇药业股份有限公司第五届监事会第十三次会议于2025年9月29日以现场结合通讯方式召开，会议审议通过《关于部分募集资金投资项目延期的议案》。表决结果为同意3票，反对0票，弃权0票，议案获通过。备查文件为经与会监事签字的会议决议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092900035714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2569774186","title":"9月24日天宇股份现1笔折价21.44%的大宗交易 合计成交4846.07万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2569774186","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2569774186?lang=zh_cn&edition=full","pubTime":"2025-09-24 17:17","pubTimestamp":1758705465,"startTime":"0","endTime":"0","summary":"证券之星消息，9月24日天宇股份发生大宗交易，交易数据如下：大宗交易成交价格20.48元，相对当日收盘价折价21.44%，成交236.62万股，成交金额4846.07万元，买方营业部为机构专用，卖方营业部为浙商证券股份有限公司台州环城东路证券营业部。近三个月该股共发生2笔大宗交易，合计成交2.87万手，折价成交2笔。截至2025年9月24日收盘，天宇股份报收于26.07元，上涨1.84%，换手率1.07%，成交量2.26万手，成交额5860.54万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092400029815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2567135301","title":"天宇股份（300702）股东屠勇军质押1000万股，占总股本2.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2567135301","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2567135301?lang=zh_cn&edition=full","pubTime":"2025-09-15 18:28","pubTimestamp":1757932110,"startTime":"0","endTime":"0","summary":"证券之星消息，天宇股份9月15日公开信息显示，股东屠勇军向中国银河证券股份有限公司合计质押1000.0万股，占总股本2.87%。质押详情见下表：截止本公告日，股东林洁已累计质押股份2863.6万股，占其持股总数的23.47%，股东屠勇军已累计质押股份2780.0万股，占其持股总数的48.68%。天宇股份主营业务：化学原料药及中间体的研发、注册、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025091500026454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2564632453","title":"天宇股份(300702.SZ)：坎地沙坦酯片完成药品注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2564632453","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564632453?lang=zh_cn&edition=full","pubTime":"2025-09-04 16:09","pubTimestamp":1756973365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天宇股份(300702.SZ)公告，公司全资子公司浙江诺得药业有限公司(简称“诺得药业”)于近日收到国家药品监督管理局核准签发的关于坎地沙坦酯片的《药品注册证书》。坎地沙坦酯片适用于原发性高血压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1341454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2564598890","title":"9月1日天宇股份涨6.08%，兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2564598890","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2564598890?lang=zh_cn&edition=full","pubTime":"2025-09-01 16:29","pubTimestamp":1756715379,"startTime":"0","endTime":"0","summary":"证券之星消息，9月1日天宇股份涨6.08%，收盘报28.44元，换手率6.29%，成交量13.29万手，成交额3.74亿元。重仓天宇股份的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级1家，增持评级2家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。该公募基金现任基金经理为陈旭。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025090100021310.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2563235110","title":"天宇股份最新公告：子公司制剂产品首次获得美国FDA批准文号","url":"https://stock-news.laohu8.com/highlight/detail?id=2563235110","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2563235110?lang=zh_cn&edition=full","pubTime":"2025-08-29 20:21","pubTimestamp":1756470088,"startTime":"0","endTime":"0","summary":"天宇股份公告称，公司全资子公司诺得药业向美国FDA申报的奥美沙坦酯氢氯噻嗪片的新药简略申请已获得批准。该药品主要用于治疗高血压，由Cosette Pharmaceuticals, Inc研发，于2003年6月在美国上市。诺得药业该药品于2020年2月获得美国FDA受理，截至目前累计研发投入约762.77万元。公司产品奥美沙坦酯氢氯噻嗪片成功获得美国FDA上市批准，是制剂产品首次获得美国FDA批准，标志着公司制剂产品正式取得美国市场准入资格，进一步深化了海外业务布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082900041786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0},{"id":"2562271816","title":"【机构调研记录】凯石基金调研天宇股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2562271816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562271816?lang=zh_cn&edition=full","pubTime":"2025-08-26 08:01","pubTimestamp":1756166507,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月25日披露的机构调研信息，凯石基金近期对1家上市公司进行了调研，相关名单如下：1）天宇股份 调研纪要：报告期内，天宇股份各业务板块毛利率同比环比均提升，主要得益于规模效应和降本增效。凯石基金成立于2017年，截至目前，资产管理规模1.06亿元，排名203/210；资产管理规模1.06亿元，排名175/210；管理公募基金数7只，排名163/210；旗下公募基金经理4人，排名156/210。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082600009902.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2562229651","title":"天宇股份股价微跌0.11% 机构调研透露上半年营收增长23.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2562229651","media":"金融界","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2562229651?lang=zh_cn&edition=full","pubTime":"2025-08-26 01:02","pubTimestamp":1756141340,"startTime":"0","endTime":"0","summary":"天宇股份8月25日股价报27.57元，较前一交易日下跌0.03元，跌幅0.11%。天宇股份属于化学制药板块，主营业务涵盖仿制药原料药及中间体、CDMO原料药及中间体、制剂等。2025年上半年，公司实现营业收入15.67亿元，同比增长23.87%，毛利率提升至38%。8月24日，天宇股份接待了华创证券研究所、中金证券、中信证券等多家机构调研。8月25日，天宇股份主力资金净流出250.81万元，占流通市值的0.04%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/08/26010252679923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["300702"],"gpt_icon":0},{"id":"2561253458","title":"天宇股份（300702）2025年中报简析：营收净利润同比双双增长，应收账款上升","url":"https://stock-news.laohu8.com/highlight/detail?id=2561253458","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561253458?lang=zh_cn&edition=full","pubTime":"2025-08-24 06:18","pubTimestamp":1755987495,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期天宇股份发布2025年中报。截至本报告期末，公司营业总收入15.67亿元，同比上升23.87%，归母净利润1.5亿元，同比上升180.96%。按单季度数据看，第二季度营业总收入8.08亿元，同比上升40.31%，第二季度归母净利润6332.84万元，同比上升398.73%。本报告期天宇股份应收账款上升，应收账款同比增幅达63.81%。本次财报公布的各项数据指标表现尚佳。应收款项变动幅度为51.89%,原因:销售增加导致应收货款增加。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025082400001765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702"],"gpt_icon":0},{"id":"2561719594","title":"天宇股份(300702.SZ)发布上半年业绩，归母净利润1.5亿元，增长180.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2561719594","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2561719594?lang=zh_cn&edition=full","pubTime":"2025-08-22 20:10","pubTimestamp":1755864651,"startTime":"0","endTime":"0","summary":"智通财经APP讯，天宇股份(300702.SZ)发布2025年半年度报告，该公司营业收入为15.67亿元，同比增长23.87%。归属于上市公司股东的净利润为1.5亿元，同比增长180.96%。归属于上市公司股东的扣除非经常性损益的净利润为1.41亿元，同比增长125.11%。基本每股收益为0.43元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1333777.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"天宇股份(300702.SZ)发布上半年业绩，归母净利润1.5亿元，增长180.96%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300702"],"gpt_icon":0},{"id":"2558646455","title":"天宇股份最新公告：公司原料药获得CEP证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2558646455","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558646455?lang=zh_cn&edition=full","pubTime":"2025-08-12 18:29","pubTimestamp":1754994599,"startTime":"0","endTime":"0","summary":"天宇股份(300702.SZ)公告称，公司收到欧洲药品质量管理局签发的关于替米沙坦工艺II原料药的欧洲药典适用性认证证书。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081200033452.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300702","BK0239"],"gpt_icon":0},{"id":"2558063062","title":"8月11日天宇股份涨14.50%，兴业医疗保健混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2558063062","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2558063062?lang=zh_cn&edition=full","pubTime":"2025-08-11 16:27","pubTimestamp":1754900846,"startTime":"0","endTime":"0","summary":"证券之星消息，8月11日天宇股份涨14.50%创60日新高，收盘报29.77元，换手率12.62%，成交量26.66万手，成交额7.87亿元。重仓天宇股份的公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级2家，增持评级1家。根据2025基金半年报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为兴业基金的兴业医疗保健混合A。该公募基金现任基金经理为陈旭。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025081100025877.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300702"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1765364586049,"stockEarnings":[{"period":"1week","weight":-0.0089},{"period":"1month","weight":-0.0298},{"period":"3month","weight":-0.0822},{"period":"6month","weight":-0.0037},{"period":"1year","weight":0.4018},{"period":"ytd","weight":0.4699}],"compareEarnings":[{"period":"1week","weight":0.003},{"period":"1month","weight":-0.022},{"period":"3month","weight":0.0255},{"period":"6month","weight":0.149},{"period":"1year","weight":0.149},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"浙江天宇药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15238人(较上一季度减少8.06%)","perCapita":"13857股","listingDate":"2017-09-19","address":"浙江省台州市黄岩区黄岩江口化工开发区","registeredCapital":"34797万元","survey":" 浙江天宇药业股份有限公司的主营业务是中间体、原料药以及制剂业务的研发、生产与销售。公司的主要产品是降血压类原料药及中间体、降血糖类原料药及中间体、抗凝血类原料药及中间体、制剂类、抗哮喘类原料药及中间体、降血脂类原料药及中间体。","listedPrice":22.41},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"天宇股份,300702,天宇股份股票,天宇股份股票老虎,天宇股份股票老虎国际,天宇股份行情,天宇股份股票行情,天宇股份股价,天宇股份股市,天宇股份股票价格,天宇股份股票交易,天宇股份股票购买,天宇股份股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"天宇股份(300702)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供天宇股份(300702)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}